SE423385B - Forfarande for framstellning av cykloalitatiska aminosyror och estrar derav - Google Patents

Forfarande for framstellning av cykloalitatiska aminosyror och estrar derav

Info

Publication number
SE423385B
SE423385B SE7514442A SE7514442A SE423385B SE 423385 B SE423385 B SE 423385B SE 7514442 A SE7514442 A SE 7514442A SE 7514442 A SE7514442 A SE 7514442A SE 423385 B SE423385 B SE 423385B
Authority
SE
Sweden
Prior art keywords
cycloalitatic
esters
procedure
preparation
amino acids
Prior art date
Application number
SE7514442A
Other languages
English (en)
Swedish (sv)
Other versions
SE7514442L (sv
Inventor
G Satzinger
M Herrmann
J Hartenstein
W Heldt
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=5934284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE423385(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of SE7514442L publication Critical patent/SE7514442L/xx
Publication of SE423385B publication Critical patent/SE423385B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE7514442A 1974-12-21 1975-12-19 Forfarande for framstellning av cykloalitatiska aminosyror och estrar derav SE423385B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2460891A DE2460891C2 (de) 1974-12-21 1974-12-21 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Publications (2)

Publication Number Publication Date
SE7514442L SE7514442L (sv) 1976-06-22
SE423385B true SE423385B (sv) 1982-05-03

Family

ID=5934284

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7514442A SE423385B (sv) 1974-12-21 1975-12-19 Forfarande for framstellning av cykloalitatiska aminosyror och estrar derav

Country Status (16)

Country Link
US (1) US4024175A (show.php)
JP (1) JPS5324064B2 (show.php)
AT (1) AT340892B (show.php)
BE (1) BE836835A (show.php)
CA (1) CA1052811A (show.php)
CH (3) CH612664A5 (show.php)
DE (1) DE2460891C2 (show.php)
DK (1) DK147706C (show.php)
ES (1) ES443723A1 (show.php)
FI (1) FI62282C (show.php)
FR (1) FR2294697A1 (show.php)
GB (1) GB1465229A (show.php)
IE (1) IE42382B1 (show.php)
LU (1) LU74058A1 (show.php)
NL (1) NL181006C (show.php)
SE (1) SE423385B (show.php)

Families Citing this family (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2611690A1 (de) * 1976-03-19 1977-09-22 Goedecke Ag Cyclische sulfonyloxyimide
JPS5776189U (show.php) * 1980-10-28 1982-05-11
JPS6152583U (show.php) * 1984-09-11 1986-04-09
JPS61139881U (show.php) * 1985-02-21 1986-08-29
US4876279A (en) * 1986-05-05 1989-10-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
US4960931A (en) * 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
YU162789A (en) * 1988-09-01 1990-12-31 Lonza Ag 2-aza-4-(alcoxycarbonyl) spiro/4,5/decan-3-ones
DE3928182A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von gabapentin
US5132451A (en) * 1989-08-25 1992-07-21 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
US5319135A (en) * 1989-08-25 1994-06-07 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
PH27359A (en) * 1989-08-25 1993-06-21 Warner Lambert Co Process for cyclic amino acid anticonvulsant compounds
DE3928184A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
GB8925933D0 (en) * 1989-11-16 1990-01-04 Pfizer Ltd Glutaric acid derivatives and preparation thereof
US5157138A (en) * 1989-11-16 1992-10-20 Pfizer, Inc. Glutaric acid derivatives and preparation thereof
FI905584A7 (fi) * 1989-11-16 1991-05-17 Lonza Ag Menetelmä 1-(aminometyyli)sykloheksaanietikkahapon valmistamiseksi
US5136091A (en) * 1989-11-16 1992-08-04 Lonza Ltd. Process for the production of 1-(aminomethyl) cyclohexane acetic acid
US5260467A (en) * 1989-11-16 1993-11-09 Pfizer Inc. Glutaric acid derivatives and preparation thereof
US5149870A (en) * 1989-11-16 1992-09-22 Lonza Ltd. Process for the production of 1-(aminomethyl)cyclohexane acetic acid
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
EA001534B1 (ru) * 1996-02-07 2001-04-23 Варнер-Ламберт Компани Производные циклической аминокислоты или их фармацевтически приемлемые соли, фармацевтическая композиция и способ лечения депрессии, состояний паники, страха и болевых ощущений
BR9708200A (pt) * 1996-03-14 1999-07-27 Warner Lambert Co Aminoácidos cíclicos substituídos como agentes farmacéuticos
CZ287598A3 (cs) * 1996-03-14 1999-02-17 Warner-Lambert Company Přemostěné cyklické aminokyseliny
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
DE69737719D1 (de) * 1996-10-23 2007-06-21 Warner Lambert Co Substituierte gamma-aminobuttersäurederivate als arzneimittel
US6255526B1 (en) 1996-12-24 2001-07-03 Teva Pharmaceutical Industries Ltd. Preparation of gabapentin
IL119890A (en) * 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
HRP980342A2 (en) * 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
US6329429B1 (en) 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
US6194459B1 (en) 1997-08-19 2001-02-27 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotors stimulants
ATE311867T1 (de) * 1997-09-08 2005-12-15 Warner Lambert Co Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen
US6294690B1 (en) 1997-10-07 2001-09-25 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
ATE323067T1 (de) * 1997-10-27 2006-04-15 Warner Lambert Co Zyklische aminosäuren und deren derivate als arzneimittel
US6984659B2 (en) * 1997-11-18 2006-01-10 Klinikum Der Albert-Ludwigs Universitaet 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
TR200001800T2 (tr) 1997-12-16 2001-03-21 Warner-Lambert Company -4(3)-İkameli -4(3)- aminometil-(tio) piran veya- piperidin türevleri (=Gabapentin analogları), hazırlanmaları ve nörolojik hastalıkların tedavisinde kullanımları
NZ503981A (en) 1997-12-16 2002-12-20 Warner Lambert Co Novel amines, pharmaceutical compositions containing these amines, and uses thereof
SI1047678T1 (en) * 1997-12-16 2005-02-28 Warner-Lambert Company Llc 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
WO1999037296A1 (en) * 1998-01-23 1999-07-29 Warner-Lambert Company Gabapentin and its derivatives for the treatment of muscular and skeletal pain
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
KR100669280B1 (ko) * 1998-05-15 2007-01-17 워너-램버트 캄파니 엘엘씨 감마-아미노부티르산 유도체 포함 고상 조성물 및 그의제조 방법
PL204921B1 (pl) 1998-05-15 2010-02-26 Warner Lambert Co Stabilizowana kompozycja farmaceutyczna zawierająca 4-amino-3-podstawioną pochodną kwasu butanowego i α-aminokwas oraz sposób jej wytwarzania
ES2137137B1 (es) * 1998-05-25 2000-08-16 Medichem Sa Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
CA2322558C (en) 1998-05-26 2006-04-11 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
ITMI981535A1 (it) * 1998-07-03 2000-01-03 Zambon Spa Processo per la preparazione di gabapentina
US20030045500A1 (en) * 1998-07-09 2003-03-06 Leslie Magnus Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
FR2781793B1 (fr) 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
HU225502B1 (en) * 1998-12-29 2007-01-29 Richter Gedeon Vegyeszet Process for producing 1-(amino-metyl)-cyclohexene-acetic-acid and intermediates
IT1311984B1 (it) 1999-03-26 2002-03-22 Bioindustria Lab Italiano Medi Procedimento per la preparzione di gabapentin.
JP2002541215A (ja) * 1999-04-09 2002-12-03 ユーロ−セルティック エス． ア． ナトリウムチャネル遮断薬組成物およびその使用
MXPA01011059A (es) * 1999-05-28 2002-06-04 Warner Lambert Co Analogos gaba 3-heteroarilalquilo sustituidos.
US6710190B1 (en) * 1999-05-28 2004-03-23 Warner-Lambert Company 3-heteroarylalkyl substituted gaba analogs
HK1046401B (zh) * 1999-06-10 2005-12-02 沃尼尔‧朗伯有限责任公司 单和双取代的3-丙基-γ-氨基丁酸
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US6294198B1 (en) 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB2362646A (en) * 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
CZ200339A3 (cs) * 2000-06-16 2003-06-18 Teva Pharmaceutical Industries Ltd. Stabilní gabapentin vykazující neutrální pH
EP1384473A1 (en) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chlorine ion
DK1289364T3 (da) 2000-06-16 2004-04-13 Teva Pharma Stabil gapapentin som indeholder mere end 20 ppm chlorioner
HUP0300833A3 (en) * 2000-06-26 2009-08-28 Warner Lambert Co Gabapentin analogues for treating sleep disorders
GB2364049A (en) * 2000-06-28 2002-01-16 Warner Lambert Co Cyclic ketones and their use in the synthesis of amino acids
DK1317426T3 (da) * 2000-09-14 2006-01-09 Gruenenthal Gmbh Betal-thio-aminosyrer
WO2002032376A2 (en) * 2000-10-06 2002-04-25 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
US6992076B2 (en) * 2000-10-06 2006-01-31 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US6620829B2 (en) * 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
IT1319234B1 (it) * 2000-10-23 2003-09-26 Zambon Spa Processo di preparazione di gabapentina.
GB2368579A (en) * 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
AU2002213506A1 (en) * 2000-11-02 2002-05-15 Teva Pharmaceutical Industries Ltd Improved process for production of gabapentin intermediate
PT1337271E (pt) * 2000-11-30 2005-01-31 Pfizer Prod Inc Combinacao de agonistas de gaba e inibidores de sorbitol desidrogenase
PL365378A1 (en) * 2000-11-30 2005-01-10 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
IT1319674B1 (it) * 2000-12-01 2003-10-23 Erregierre Spa Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
WO2002074727A1 (en) * 2001-03-16 2002-09-26 Solchem Italiana S.P.A. A process for the preparation of cyclic amino acids
ITMI20011132A1 (it) 2001-05-29 2002-11-29 Procos Spa Procedimento per la preparazione dell'acido 1-amminometil-1-cicloesanacetico
EP1412324A4 (en) * 2001-06-11 2004-09-29 Xenoport Inc AMINO ACID CONJUGATES THAT RESULT IN GABA ANALOGA LASTING SYSTEMIC CONCENTRATIONS
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ATE380029T1 (de) * 2001-06-11 2007-12-15 Xenoport Inc Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
IL144066A0 (en) * 2001-06-28 2002-04-21 Bromine Compounds Ltd Process for the preparation of 1,1-cyclohexane diacetic monoamide
ITMI20011772A1 (it) 2001-08-10 2003-02-10 A M S A Anonima Materie Sint E Processo per la preparazione della 2,5-bis-(2,2,2-trifluoroetossi)-n-(2-piperidilmetil)-benzamide(flecainide)
ATE317280T1 (de) 2001-09-03 2006-02-15 Newron Pharm Spa Pharmazeutische zusammensetzung mit gabapentin oder deren analog und einem alpha-aminoamid und analgetische verwendung dieser zusammensetzung
US6800782B2 (en) * 2001-10-09 2004-10-05 Warner-Lambert Co. Anhydrous crystalline forms of gabapentin
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
ITMI20012750A1 (it) 2001-12-21 2003-06-21 Procos Spa Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
NZ532624A (en) * 2002-01-31 2007-05-31 Warner Lambert Co Alpha2delta ligands to treat tinnitus
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2002316231A1 (en) * 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
WO2003080588A1 (en) 2002-03-20 2003-10-02 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
EP1494996A1 (en) * 2002-04-16 2005-01-12 Taro Pharmaceutical Industries Limited Process for preparing gabapentin
CA2484891A1 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
AU2003243180A1 (en) * 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
JP2005534678A (ja) * 2002-06-27 2005-11-17 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 注意欠陥多動性障害の治療方法
CA2395931A1 (en) * 2002-08-07 2004-02-07 Bernard Charles Sherman Solid compositions comprising gabapentin having improved stability
US7053122B2 (en) * 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US20040092522A1 (en) * 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US7419981B2 (en) * 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US20040092591A1 (en) * 2002-08-15 2004-05-13 Blakemore David Clive Therapeutic use of fused bicyclic or tricyclic amino acids
US20040092498A1 (en) * 2002-08-16 2004-05-13 David Blakemore Substituted glycine derivatives for use as medicaments
ITMI20022071A1 (it) * 2002-10-01 2004-04-02 Erregierre Spa Processo di sintesi dell'acido 1-(aminometil)cicloesanacetico cloridato.
US7659305B2 (en) * 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
WO2004046084A1 (en) * 2002-11-18 2004-06-03 Nicholas Piramal India Limited Improved process for preparation of gabapentin
WO2004046108A1 (en) * 2002-11-20 2004-06-03 Hikal Ltd. An improved process for the preparation of gabalactam
US7060727B2 (en) * 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
US20040162351A1 (en) * 2002-12-11 2004-08-19 Gallop Mark A. Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity
US20040180958A1 (en) * 2002-12-13 2004-09-16 Taylor Charles Price Method of treatment
EP1572184A1 (en) * 2002-12-13 2005-09-14 Warner-Lambert Company Gabapentin analogues for fibromyalgia and other related disorders
PL377662A1 (pl) * 2002-12-13 2006-02-06 Warner-Lambert Company Llc Pregabalina i jej pochodne w leczeniu fibromialgii i innych zaburzeń pokrewnych
WO2004054566A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Pregabalin derivatives for the treatment of fibromyalgia and other disorders
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
GB0301143D0 (en) * 2003-01-17 2003-02-19 Amedis Pharm Ltd Compounds and their use
EP1592661A2 (en) * 2003-01-22 2005-11-09 Warner-Lambert Company LLC Cyclopropyl beta-amino acid derivatives
EP1603890A1 (en) * 2003-03-07 2005-12-14 Warner-Lambert Company LLC TETRAZOLE AND OXADIAZOLONE SUBSTITUTED &bgr;-AMINO ACID DERIVATIVES
WO2004093866A1 (en) * 2003-03-25 2004-11-04 Kiel Laboratories, Inc. Process for preparing phenolic acid salts of gabapentin
WO2004093827A2 (en) * 2003-03-25 2004-11-04 Kiel Laboratories, Inc. Phenolic acid salts of gabapentin in solid dosage forms and methods of use
WO2004093867A2 (en) * 2003-03-25 2004-11-04 Kiel Laboratories, Inc. Phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms and methods of use
CA2520468A1 (en) * 2003-03-31 2004-10-21 Xenoport, Inc. Treating or preventing hot flashes using prodrugs of gaba analogs
US20040214893A1 (en) * 2003-04-11 2004-10-28 Matthew Peterson Gabapentin compositions
ITMI20030825A1 (it) * 2003-04-18 2004-10-19 Farchemia Srl Procedimento per la preparazione di gabapentin esente da
WO2004093780A2 (en) * 2003-04-21 2004-11-04 Matrix Laboratories Ltd Process for the preparation of gabapentin form-ii
AU2004237951A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
BRPI0411654A (pt) * 2003-06-19 2006-08-08 Pfizer Prod Inc preparação biocatalìtica de ácido 1-cianocicloexanoacético
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
WO2005002585A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
WO2005046566A2 (en) * 2003-08-04 2005-05-26 Sun Pharmaceutical Industries Limited Stable gabapentin containing composition
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
EP1670451A4 (en) * 2003-09-11 2009-10-21 Xenoport Inc TREATMENT AND / OR PREVENTION OF URINARY INCONTINENCE AND PROMOTERS OF GABA ANALOGS
CA2538412A1 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders
CA2537402C (en) * 2003-09-12 2009-05-05 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
NZ545989A (en) * 2003-09-17 2009-10-30 Xenoport Inc Treating or preventing restless legs syndrome using prodrugs of gaba analogs
ATE516801T1 (de) * 2003-10-14 2011-08-15 Xenoport Inc Kristalline form eines gamma-aminobuttersäure- analogons
ITMI20032165A1 (it) * 2003-11-11 2005-05-12 Zambon Spa Processo di preparazione di gabapentina
US20050176680A1 (en) 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
WO2005082372A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
US20050187295A1 (en) * 2004-02-19 2005-08-25 Surendra Kalyan Processes for the preparation of gabapentin
CA2570255A1 (en) * 2004-03-17 2005-09-22 Hikal Limited 4-t-butylgabapentin and its synthesis
ITMI20040579A1 (it) * 2004-03-25 2004-06-25 Zambon Spa Processo di preparazione di gabapentina
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
US20080261984A1 (en) * 2004-06-09 2008-10-23 Pfizer Inc. Use of S,S-Reboxetine in the Treatment of Pain
GB0416228D0 (en) * 2004-07-20 2004-08-25 Sandoz Ind Products S A Process for the preparation of gabapentin
GB0419849D0 (en) * 2004-09-07 2004-10-13 Pfizer Ltd Pharmaceutical combination
DK1809271T5 (da) * 2004-09-10 2010-12-06 Newron Pharm Spa Anvendelse af (R)-(halogenbenzyloxy)benzylaminopropanamider som natrium- og/eller calciumkanalselektive modulatorer
CN102429882B (zh) * 2004-11-04 2015-03-25 什诺波特有限公司 加巴喷丁前体药物持续释放口服剂型
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
KR20080050511A (ko) 2005-09-23 2008-06-05 얀센 파마슈티카 엔.브이. 테트라하이드로-사이클로펜틸 피라졸 카나비노이드모듈레이터
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
JP2009508953A (ja) * 2005-09-23 2009-03-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヘキサヒドロ−シクロヘプタピラゾール系カンナビノイドモジュレーター
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
DK1931335T3 (da) * 2005-09-23 2010-06-07 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl-pyrazol-cannabinoid-modulatorer
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EP1979593B1 (en) * 2006-02-03 2017-12-06 Rolls-Royce Corporation Gas turbine engine fuel system with fuel metering valve
EP1820502A1 (en) 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
US7795294B2 (en) * 2006-02-14 2010-09-14 Janssen Pharmaceutica N.V. Tetrahydro-2H-indazole pyrazole cannabinoid modulators
CN101420947A (zh) * 2006-03-06 2009-04-29 辉瑞产品公司 用于非恢复性睡眠的α-2-δ配体
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
US8012957B2 (en) * 2006-03-27 2011-09-06 Janssen Pharmaceutica Nv Tetrahydro-1H-1,2,6-triaza-azulene cannabinoid modulators
AU2007249435A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7442834B2 (en) * 2006-06-12 2008-10-28 Zhejiang Chiral Medicine Chemicals Co., Ltd. Process suitable for industrial scale production of gabapentin
CA2660769C (en) * 2006-06-30 2013-12-03 Zach System S.P.A. Process for preparing gabapentin
BRPI0716604A2 (pt) 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2672044A1 (en) * 2006-12-08 2008-06-19 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
JP5308350B2 (ja) 2006-12-22 2013-10-09 レコルダーティ アイルランド リミテッド α２δリガンドおよびＮＳＡＩＤを用いた下部尿路機能障害の併用療法
KR20090121388A (ko) * 2007-03-15 2009-11-25 썬 파마 어드밴스트 리서치 컴패니 리미티드 신규 전구약물
WO2008157408A2 (en) * 2007-06-15 2008-12-24 Xenoport, Inc. Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US20090062392A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched gabapentin
WO2009061934A1 (en) * 2007-11-06 2009-05-14 Xenoport, Inc. Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
ES2601852T3 (es) * 2008-01-25 2017-02-16 Xenoport, Inc. Forma cristalina de sales de calcio de ácidos (3S)-aminometil-5-metil-hexanoicos y métodos de uso
WO2009094563A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
WO2010042759A2 (en) 2008-10-08 2010-04-15 Kyphia Pharmaceuticals Inc Gaba conjugates and methods of use thereof
US9192681B2 (en) 2009-02-24 2015-11-24 Nektar Therapeutics Oligomer-amino acid conjugates
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20110130454A1 (en) * 2009-11-24 2011-06-02 Xenoport, Inc. Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
ES2758554T3 (es) 2009-12-08 2020-05-05 Univ Case Western Reserve Aminoácidos gama para tratamiento de trastornos oculares
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2368872A1 (en) 2010-03-25 2011-09-28 Serichim S.r.l. Process for the preparation of Gabapentin
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2575798B1 (en) 2010-06-01 2017-08-09 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs
US8431739B2 (en) 2010-06-14 2013-04-30 Divi's Laboratories, Ltd. Process for the preparation of gabapentin
RU2544552C2 (ru) 2010-07-30 2015-03-20 Торэй Индастриз, Инк. Терапевтическое средство или профилактическое средство для нейропатической боли
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
JP2013216580A (ja) * 2010-08-06 2013-10-24 Kyorin Pharmaceutical Co Ltd ビシクロ［２．２．２］オクチルアミン誘導体の製造方法
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2530072A1 (en) 2011-06-03 2012-12-05 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
ITMI20131757A1 (it) 2013-10-22 2015-04-23 Zach System Spa Processo di preparazione di gabapentina
CN105392891B (zh) 2013-11-01 2021-02-12 株式会社糖锁工学研究所 具有硫醇基的d-型或l-型氨基酸衍生物的制造方法
MA39146A1 (fr) 2013-12-17 2017-11-30 Esteve Labor Dr Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma
MX2016007285A (es) 2013-12-17 2016-08-04 Esteve Labor Dr Combinaciones de inhibidores de la captacion de serotonina-norepinefrina (irsn) y ligandos de receptores sigma.
EP2923694B1 (en) 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
TWI808952B (zh) 2016-12-16 2023-07-21 瑞士商愛杜西亞製藥有限公司 包含t型鈣通道阻斷劑之醫藥組合
MX384760B (es) 2018-07-04 2025-03-14 Federico Amezcua Amezcua Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático.
US10399926B1 (en) 2018-08-01 2019-09-03 Divi's Laboratories Ltd. Process for the preparation of gabapentin
WO2020074944A1 (en) 2018-10-11 2020-04-16 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
EP4049679A4 (en) 2019-10-25 2023-11-01 Kyoto University Preventative or therapeutic agent for tauopathy
IL296166A (en) 2020-03-04 2022-11-01 Pleopharma L L C Methods and preparations for treating cannabis use disorder and facilitating cannabinoid withdrawal
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
GB2625579A (en) 2022-12-21 2024-06-26 Novumgen Ltd An orally disintegrating tablet containing gabapentin or pharmaceutically acceptable salts thereof and the process of preparing the same

Also Published As

Publication number Publication date
FI62282B (fi) 1982-08-31
NL181006C (nl) 1987-06-01
AU8774175A (en) 1977-06-23
DK581475A (da) 1976-01-22
GB1465229A (en) 1977-02-23
FR2294697B1 (show.php) 1978-07-28
BE836835A (fr) 1976-06-18
ATA975075A (de) 1977-05-15
CH612665A5 (show.php) 1979-08-15
FI62282C (fi) 1982-12-10
SE7514442L (sv) 1976-06-22
FI753613A7 (show.php) 1976-06-22
JPS5324064B2 (show.php) 1978-07-18
LU74058A1 (show.php) 1976-07-20
AT340892B (de) 1978-01-10
IE42382L (en) 1976-06-21
NL181006B (nl) 1987-01-02
US4024175A (en) 1977-05-17
CA1052811A (en) 1979-04-17
JPS5188940A (show.php) 1976-08-04
CH612664A5 (show.php) 1979-08-15
DK147706B (da) 1984-11-19
IE42382B1 (en) 1980-07-30
DE2460891A1 (de) 1976-07-01
NL7514900A (nl) 1976-06-23
DE2460891C2 (de) 1982-09-23
DK147706C (da) 1985-05-13
CH612666A5 (show.php) 1979-08-15
FR2294697A1 (fr) 1976-07-16
ES443723A1 (es) 1977-04-16

Similar Documents

Publication Publication Date Title
SE423385B (sv) Forfarande for framstellning av cykloalitatiska aminosyror och estrar derav
NO147792C (no) Fremgangsmaate for fremstilling av estere av dihalogen-vinylcyklopropankarboksylsyrer
SE427029B (sv) Forfarande for framstellning av acetyleniska aminosyror
SE431746B (sv) Forfarande for framstellning av d-fenylglycinamid eller d-fenylglycin och l-fenylglycin
SE436353B (sv) Forfarande for framstellning av aminosyraestrar
SE414181B (sv) Forfarande for framstellning av polylaktoner bestaende av inter- och intramolekylera estrar av poly-alfa-hydroxiakrylsyror
SE423097B (sv) Analogiforfarande for framstellning av apovinkaminoestrar
SE7511931L (sv) Penicilliner och forfarande for framstellning derav
SE416469B (sv) Forfarande for framstellning av aralkansyror innehallande dihydrofuran - eller dihydropyranringar
SE394809B (sv) Analogiforfarande for framstellning av antidepressivt verkande aralkylestrar av aminosyror
NO143901C (no) Fremgangsmaate for fremstilling av aminosyrer
SE407150B (sv) Injektionsspruta och forfarande for framstellning av densamma
NO143502C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrano-kinolinkarboksylsyrer
SE7600991L (sv) Forfarande for framstellning av fenyl- och bensylfosfonatestrar
SE430416B (sv) Forfarande for framstellning av alkoxisubstituerade tiofenkarboxylsyror och estrar derav
SE7604669L (sv) Forfarande for framstellning av estrar av tiokarbamidsyror
SE418395B (sv) Forfarande for framstellning av indanettiksyror
SE7507795L (sv) Forfarande for framstellning av selenhaltiga aminosyrer.
SE7508715L (sv) Forfarande for framstellning av diamider av aromatiska och cykloalifatiska dikarbonsyror
SE7604940L (sv) Forfarande for framstellning av sulfamylbensoesyror
SE420835B (sv) Forfarande for framstellning av monokromonkarboxylsyror med terapentisk verkan
SE398882B (sv) Forfarande for framstellning av salter av aminosyror och polysvavelsyraestrar av naturliga glykopeptider
SE7514094L (sv) Acylaminopenicillansyror och forfarande for deras framstellning
SE417086B (sv) Forfarande for framstellning av 2-etylindan och 2-isopropylindan
SE398352B (sv) Forfarande for framstellning av x-aminocyklopropylacetamidopenicillansyror och x-aminocyklobutylacetaamidopenicillansyror

Legal Events

Date Code Title Description
SPCF Application for supplementary protection certificate filed

Free format text: 7514442

NAL Patent in force

Ref document number: 7514442-8

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 7514442-8

Format of ref document f/p: F

SPCG Supplementary protection certificate granted

Free format text: 9490104, 940325, EXPIRES: 20001219